Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating Surmodics for potential breaches of fiduciary duty and violations of law related to its transaction with GTCR, which involves a cash offer of $43.00 per share, totaling approximately $627 million in equity valuation [1][2]. Group 1: Transaction Details - Surmodics shareholders will receive $43.00 per share in cash, leading to a total equity valuation of around $627 million [2]. - The transaction agreement includes provisions that significantly limit competing offers for Surmodics, imposing a substantial penalty if a competing bid is accepted [2]. - Insiders at Surmodics are set to receive considerable benefits as part of the change of control arrangements [2]. Group 2: Investigation Focus - The investigation is centered on the conduct of Surmodics' board of directors and whether they are adequately fulfilling their fiduciary duties to all shareholders [3]. - Shareholders of Surmodics are encouraged to seek additional information regarding the investigation [3]. Group 3: Legal Context - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights across the country [4].